Recombinant Yersinia pestis bv. Antiqua Glycerol-3-phosphate acyltransferase (plsY)

What is the function of Glycerol-3-phosphate acyltransferase (plsY) in Yersinia pestis?

Glycerol-3-phosphate acyltransferase (plsY) is a critical enzyme in Y. pestis that catalyzes the first step in phospholipid biosynthesis. It specifically transfers an acyl group from acyl-CoA to glycerol-3-phosphate to form lysophosphatidic acid. This reaction represents the rate-limiting step in the de novo pathway of glycerolipid synthesis, making plsY essential for bacterial membrane formation and integrity. Unlike eukaryotic GPATs that exist in multiple isoforms with distinct subcellular localizations, bacterial plsY typically exists as a single isoform embedded in the plasma membrane where it plays a pivotal role in regulating phospholipid composition .

What expression systems are most suitable for producing recombinant Y. pestis proteins?

Based on successful recombinant Y. pestis protein expression studies, several systems have proven effective. For plsY specifically, E. coli BL21 derivatives have shown good results, particularly when optimized with appropriate chaperones. When expressing Y. pestis proteins like the F1 antigen, co-expression with periplasmic chaperones significantly enhances proper folding and solubility. For example, the F1S-V-F1 fusion protein demonstrated enhanced solubility and secretion when co-expressed with the Y. pestis Caf1M periplasmic chaperone in BL21-Star E. coli . For membrane proteins like plsY, expression systems featuring controllable promoters (such as T7-based systems) with reduced leaky expression and the ability to include fusion tags for purification and solubility enhancement are recommended.

What purification strategies work best for recombinant Y. pestis plsY?

Purification of recombinant Y. pestis plsY requires specialized approaches due to its membrane-associated nature. A recommended protocol involves:

• Initial extraction using mild detergents (0.5-1% n-dodecyl-β-D-maltoside or CHAPS)

• Sequential purification using:

  • Immobilized metal affinity chromatography (if His-tagged)

  • Anion-exchange chromatography

  • Hydrophobic interaction chromatography

This multi-step approach has been successful for other Y. pestis recombinant proteins, yielding >1mg of purified soluble protein per liter of culture . For plsY specifically, maintaining the detergent concentration above its critical micelle concentration throughout purification is essential to prevent protein aggregation and maintain enzymatic activity. Purification under native conditions rather than denaturing conditions is strongly recommended to preserve structural integrity and enzymatic function.

How can the enzymatic activity of recombinant plsY be accurately measured?

The enzymatic activity of recombinant plsY can be measured through several complementary approaches:

• Radioisotope-based assay: Using [¹⁴C]-labeled glycerol-3-phosphate and measuring the formation of radiolabeled lysophosphatidic acid

• Spectrophotometric coupled assay: Where the release of free CoA is coupled to a color-producing reaction

• HPLC-based product detection: Quantifying lysophosphatidic acid formation directly

For optimal results, enzyme activity should be assessed under physiologically relevant conditions (pH 7.2-7.4, temperature 28°C and 37°C to mimic vector and host environments). These methodologies can be adapted from those used for other GPATs while optimizing for the specific properties of bacterial plsY .

What strategies help overcome expression challenges for recombinant Y. pestis membrane proteins?

Expression of recombinant Y. pestis membrane proteins like plsY presents several challenges. Successful strategies include:

• Codon optimization: Adjusting the codons to match E. coli preference patterns increases translation efficiency

• Fusion partners: Adding solubility-enhancing tags such as MBP, SUMO, or thioredoxin

• Controlled expression: Using lower cultivation temperatures (16-25°C) and reduced inducer concentrations

• Co-expression with chaperones: Including specific molecular chaperones helps proper folding

For Y. pestis proteins specifically, co-expression with native chaperones has proven particularly effective. For example, the co-expression of the Y. pestis Caf1M periplasmic chaperone significantly enhanced the solubility and proper processing of recombinant F1-antigen variants . This approach can be adapted for plsY by identifying and co-expressing its native interacting proteins or general membrane protein chaperones.

How can structure-function analyses of plsY inform antimicrobial development against Y. pestis?

Structure-function analyses of Y. pestis plsY can significantly advance antimicrobial development through several approaches:

• Structural determination: X-ray crystallography or cryo-EM studies of plsY can reveal essential catalytic residues and binding pockets unique to the bacterial enzyme compared to eukaryotic counterparts

• Inhibitor screening: High-throughput screening of compound libraries against purified recombinant plsY can identify lead molecules

• Rational drug design: In silico modeling using solved structures can guide optimization of inhibitor binding and specificity

The critical role of plsY in phospholipid biosynthesis makes it an attractive antimicrobial target, as its inhibition would disrupt membrane integrity. Since GPATs in bacteria differ significantly from mammalian isoforms in structure and substrate specificity, inhibitors can be designed with minimal off-target effects on host cells . Recent studies with GPAT inhibitors like FSG67 have demonstrated efficacy against metabolic conditions, suggesting similar approaches could be applied to develop plsY-specific inhibitors for Y. pestis .

What is the relationship between plsY activity and Y. pestis virulence during infection?

The relationship between plsY activity and Y. pestis virulence is multifaceted:

• Membrane phospholipid composition: PlsY activity directly influences membrane phospholipid composition, affecting bacterial survival under stress conditions encountered during infection

• Temperature adaptation: When transitioning from flea vector (28°C) to mammalian host (37°C), Y. pestis undergoes significant membrane remodeling, in which plsY plays a crucial role

• Interaction with host immune system: Membrane phospholipid composition affects recognition by host immune receptors and resistance to antimicrobial peptides

Studies of other Y. pestis virulence factors have shown that membrane-associated components significantly impact pathogenesis. For example, the F1 antigen forms a capsule-like structure that serves as a major virulence factor . Similarly, the proper functioning of plsY ensures appropriate membrane composition required for the expression and function of various virulence factors, including the type III secretion system that delivers effector proteins into host cells.

How do genetic variations in plsY across Y. pestis strains correlate with virulence differences?

Genetic variations in plsY across Y. pestis strains may contribute to virulence differences through several mechanisms:

• Enzymatic efficiency: Amino acid substitutions can alter catalytic efficiency, affecting growth rates under different conditions

• Substrate preference: Variations may influence acyl chain preference, resulting in distinct membrane compositions

• Temperature sensitivity: Mutations might alter temperature optima, affecting adaptation during host transition

These correlations would need to be experimentally validated through comparative enzymatic studies of recombinant plsY variants and virulence assessment in appropriate animal models. Such studies could help explain historical differences in epidemic patterns associated with different Y. pestis biovars.

What controls are essential when working with recombinant Y. pestis plsY in enzymatic assays?

When designing enzymatic assays for recombinant Y. pestis plsY, the following controls are essential:

• Negative enzyme control: Heat-inactivated plsY or reaction mixture without enzyme to establish baseline measurements

• Substrate specificity controls: Testing activity with various acyl-CoA donors and glycerol-3-phosphate analogs

• Detergent controls: Assessing the impact of different detergents and concentrations on enzyme activity

• pH and temperature controls: Conducting assays across physiologically relevant ranges (pH 6.5-8.0, temperatures 25-40°C)

• Known GPAT inhibitor control: Using established inhibitors to validate assay sensitivity

For recombinant protein studies specifically, purification tag controls (comparing tagged versus untagged versions after cleaving the tag) are crucial to ensure tag presence doesn't artificially alter activity. Additionally, comparing recombinant plsY activity to that of crude membrane preparations from Y. pestis provides validation that the recombinant enzyme behaves similarly to the native form.

How should animal models be designed to study plsY inhibitors against Y. pestis infection?

Animal models for studying plsY inhibitors against Y. pestis should be carefully designed considering:

• Model selection: Brown Norway rats and Swiss Webster mice have been established as reliable models for Y. pestis infection studies

• Infection route: Both intranasal challenge (10³ to 10⁵ CFU) for pneumonic plague and subcutaneous inoculation for bubonic plague should be evaluated

• Treatment timing: Pre-exposure prophylaxis, post-exposure prophylaxis, and therapeutic intervention after symptom onset

• Dosing optimization: Pharmacokinetic studies to ensure inhibitors reach effective concentrations at infection sites

• Endpoints: Survival rates, bacterial burden in tissues, inflammatory markers, and histopathological changes

Standard infection protocols from Y. pestis vaccine studies can be adapted, such as those using KIM6⁺(pCD1Ap) (Mediaevalis biovar) or Y. pestis CO92 (Orientalis biovar) . For aerosolized challenges, specialized equipment like sparging liquid aerosol generators and nose-only exposure systems are recommended, with bacterial concentrations determined through impinger sampling . All studies would require proper BSL-3 containment as described for wild-type Y. pestis strains .

What approaches can resolve contradictory findings between in vitro and in vivo plsY inhibitor studies?

Resolving contradictions between in vitro and in vivo plsY inhibitor studies requires systematic investigation:

• Pharmacokinetic/pharmacodynamic analysis: Determining if the inhibitor reaches the target site at sufficient concentrations in vivo

• Metabolic stability assessment: Investigating potential metabolism or degradation of inhibitors in vivo

• Protein interaction studies: Identifying if plasma protein binding or interactions with host factors alter inhibitor availability

• Alternative target evaluation: Testing if the inhibitor affects other targets in vivo that compensate for or counteract plsY inhibition

• Bacterial adaptation responses: Examining if Y. pestis activates compensatory pathways in vivo that aren't observed in vitro

When contradictions arise, modified experimental designs such as ex vivo studies using infected tissue homogenates can serve as intermediate models to bridge the gap between in vitro and in vivo findings. Additionally, advanced imaging techniques like positron emission tomography using radiolabeled inhibitors can help track biodistribution and target engagement in real-time during infection.

How might CRISPR-Cas9 technology be applied to study plsY function in Y. pestis?

CRISPR-Cas9 technology offers powerful approaches for studying plsY function in Y. pestis:

• Conditional knockdown systems: Since plsY is likely essential, inducible knockdown rather than complete knockout would allow titrated reduction of expression

• Point mutation introduction: Creating specific amino acid substitutions to identify critical residues for catalysis and regulation

• Promoter modification: Altering expression levels to understand how plsY abundance affects membrane composition

• Tagged variant creation: Introducing fluorescent or affinity tags at the genomic locus for localization and interaction studies

Implementation would require specialized vectors adapted for Y. pestis, potentially building upon established systems used for recombinant protein expression . For biosafety considerations, initial studies could use attenuated strains lacking key virulence factors, such as the pgm locus or pCD1 plasmid, before validating findings in fully virulent strains under appropriate containment conditions.

What bioinformatic approaches can predict inhibitor binding sites on Y. pestis plsY?

Advanced bioinformatic approaches for predicting inhibitor binding sites on Y. pestis plsY include:

• Homology modeling: Generating structural models based on related bacterial acyltransferases with solved structures

• Molecular dynamics simulations: Evaluating protein flexibility and identifying transient binding pockets

• Consensus binding site prediction: Using tools like SiteMap, FTMap, and CASTp to identify potential binding pockets

• Virtual screening: Employing docking algorithms to screen compound libraries against predicted binding sites

• Machine learning approaches: Training models on known enzyme-inhibitor complexes to predict novel interaction patterns

These computational approaches should be integrated with experimental validation through techniques like hydrogen-deuterium exchange mass spectrometry or site-directed mutagenesis of predicted binding residues. The structural information can then guide rational design of inhibitors specific to Y. pestis plsY with minimal cross-reactivity to mammalian GPATs .

How could recombinant plsY be incorporated into multicomponent vaccine strategies against Y. pestis?

While plsY itself may not be an ideal vaccine antigen due to its membrane-embedded nature and potential conservation across bacterial species, recombinant plsY research could inform multicomponent vaccine strategies through several approaches:

• Adjuvant development: Purified plsY or its products could serve as pathogen-associated molecular patterns to enhance immune responses

• Carrier protein applications: Using plsY as a carrier for known protective antigens like F1 or V antigens

• Structural vaccinology: Identifying surface-exposed epitopes of plsY that could be incorporated into subunit vaccines

Current successful approaches for Y. pestis vaccines involve recombinant F1 and V antigens. Studies have shown that the structure of these antigens significantly impacts immunogenicity, with multimeric F1 providing better protection than monomeric forms . Similar structural considerations would be essential when incorporating plsY-derived components. The oral vaccine platform using attenuated Y. pseudotuberculosis expressing Y. pestis antigens offers another potential delivery system for plsY-derived vaccine components .